217087-09-7

• 常用中文名：埃索美拉唑镁(三水)
• 常用英文名：Esomeprazole magnesium
• CAS号：217087-09-7
• 分子式：C₃₄H₄₂MgN₆O₉S₂
• 分子量：767.167
• 相关类别： 信号通路 自噬 自噬
• 发布时间：2018-02-23 08:00:00
• 更新时间：2026-06-30 19:35:55
• Esomeprazole镁盐三水合物是质子泵抑制剂,能通过抑制胃壁细胞中的H+/K+ ATPase来降低酸分泌。

名称

• 中文名: D-甘露糖氨盐酸盐
• 英文名: Esomeprazole Magnesium
• 中文别名: 埃索美拉唑镁三水化合物; 艾司奥美拉唑镁三水合物; 埃索美拉唑镁三水合物检测标准品; 埃索美拉唑杂质; 埃索美拉唑镁MAGNESIUM; 埃索美拉唑镁三水物; 二(5-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基; 埃索美拉唑镁(二水/三水); 埃索美拉唑镁(三水)/A1A; 埃索美拉唑镁(艾司奥美拉唑镁); 埃索美拉唑镁三水; 拉索美拉唑镁三水合物; 二(5-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑-1-基)镁盐三水合物; 埃索美拉唑三水合镁; 埃索美拉唑镁三水合物217087-,产品批发价; 艾司奥美拉唑镁(三水); 三水埃索美拉唑镁; 埃索美拉唑三水镁盐; 镁,双[6-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基-ΚO]-1H-苯并咪唑并-ΚN3] - ,水合物(1:3),(T-4); 埃索美拉唑镁三水合物 标准品; 埃索美拉唑镁三水合物; 埃索美拉唑镁三水合物|||埃索美拉唑镁(三水)|||(S)-OMRAZOLE MAGNESIUM TRIHYDRATE; ESOMRAZOLE MAGNESIUM TRIHYDRATE 标准品; 奥美拉唑(艾司奥美拉唑镁)三水合物; 埃索美拉唑镁(三水)Esomrazole magnesium trihydrate; 埃索美拉唑镁三水合物,10 MM DMSO 溶液; 镁,双[6-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基-ΚO]-1H-苯并咪唑并-ΚN3] - ,三水合物; 埃索美拉唑镁水合物; 埃索美拉唑镁·3H2O; 埃索美拉唑镁 标准品; 埃索美拉唑镁盐三水合物; 艾司奥美拉唑三水合物
• 英文别名: Esomeprazole magnesium trihydrate; Nexium; Esomrazole Magnesium Dihydrate/Trihydrate; Esomrazole magnesium trihydrate Bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzylimidazole-1-yl) magnesium trihydrate; Omrazole Magnesium Trihydrate; Esomrazole Magnesium (25 mg); Esomrazole agnesium trihydrate; Omrazole(Esomrazole Magnesium) Trihydrate; EsoMrazole Magnesiu Trihydrate; (T-4)-Bis[5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolato]magnesium; EINECS 111-111-1; Magnesium,bis[6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-kO]-1H-benzimidazolato-kN3]-, hydrate; Omrazole / pellels; Esomrazole Magnesium trihydrate, 10 mM in DMSO; Esomrazole magnesium trihydrate CRS; EsoMrazole Meg. Trihydrate; 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, magnesium salt, hydrate (2:1:3); Esomrazole Magnesium (10 mg); bis(5-methoxy-2-[(s)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzylimidazole-1-yl) magnesium trihydrate; Nesomrazole magnesium trihydrate; Esomrzole magnesium Trihydrate; Esomrazole Mg Trihydrate; Magnesium, bis[6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-κO]-1H-benzimidazolato-κN3]-, hydrate (1:3), (T-4); Magnesium 5-methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}benzimidazol-1-ide hydrate (1:2:3); MagnesiuM,bis[6-Methoxy-2-[(S)-[(4-Methoxy-3,5-diMethyl-2-pyridinyl)Methyl]sulfinyl-kO]-1H-benziMidazolato-kN3]-, hydrate (1:3), (T-4); MFCD07698573; Magnesium 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}benzimidazol-1-ide hydrate (1:2:3); monomagnesium mono((S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide); Esomrazole Magnesium; Esomrazole magnesium trihydrate - Bio-X; ESOPMRAZOLE MG TRIHYDRATE; Esomperazole Magnessium Trihydrate; Esomrazole Magnesium Tri-Hydrate IP/Ph. Eur./BP; (S)-OMrazole MagnesiuM trihydrate; ESOMRAZOLE MAGNESIUM TRIHYDRATE; Esomeprazole (Magnesium trihydrate); Esomrazole magnesium thihydrate; EsomazoleTrihydrate; Omeprazole magnesium trihydrate; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]benzimidazol-1-ide; 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]benzimidazol-1-ide; (S)-Omeprazole magnesium trihydrate

物化性质

• 沸点: 600ºC at 760 mmHg
• 熔点: 184-189ºC (dec.)
• 分子式: C₃₄H₄₂MgN₆O₉S₂
• 分子量: 767.167
• 闪点: 316.7ºC
• 精确质量: 766.230530
• PSA: 198.59000
• LogP: 6.90950
• 外观性状: 灰白色粉末
• 蒸汽压: 2.35E-14mmHg at 25°C
• 储存条件: -20°C Freezer

生物活性

• 描述: Esomeprazole镁盐三水合物是质子泵抑制剂,能通过抑制胃壁细胞中的H+/K+ ATPase来降低酸分泌。
• 相关类别:
  信号通路 >> 自噬 >> 自噬
  信号通路 >> 跨膜转运 >> 质子泵
  研究领域 >> 其他
• 参考文献:

  [1]. Sandstr?m M, Davidson G, Tolia V et al. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. Clin Ther. 2012 Aug;34(8):1828-38.

  [2]. Wang-Smith L, Fort J, Zhang Y, Sostek M. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. J Clin Pharmacol. 2012 May;52(5):670-80.

  [3]. Johnson TJ, Hedge DD. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

  [4]. Esomeprazole

安全

• 符号: GHS07
• 信号词: Warning
• 危害声明: H302
• 警示性声明: P301 + P312 + P330
• 危害码 (欧洲): Xn
• 风险声明 (欧洲): 22
• 危险品运输编码: NONH for all modes of transport